AEGON ASSET MANAGEMENT UK Plc Decreases Holdings in IDEXX Laboratories, Inc. $IDXX

AEGON ASSET MANAGEMENT UK Plc decreased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 43.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 27,315 shares of the company’s stock after selling 20,993 shares during the quarter. AEGON ASSET MANAGEMENT UK Plc’s holdings in IDEXX Laboratories were worth $17,440,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. J.Safra Asset Management Corp acquired a new stake in IDEXX Laboratories in the 3rd quarter worth about $31,000. Armstrong Advisory Group Inc. raised its holdings in shares of IDEXX Laboratories by 55.9% during the third quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock valued at $34,000 after acquiring an additional 19 shares during the last quarter. Salomon & Ludwin LLC purchased a new position in shares of IDEXX Laboratories in the third quarter valued at approximately $35,000. WealthCollab LLC acquired a new stake in shares of IDEXX Laboratories in the second quarter worth approximately $30,000. Finally, E Fund Management Hong Kong Co. Ltd. boosted its stake in shares of IDEXX Laboratories by 62.2% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 60 shares of the company’s stock worth $38,000 after acquiring an additional 23 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Activity

In related news, EVP Nimrata Hunt sold 9,425 shares of the firm’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the completion of the sale, the executive vice president directly owned 21,149 shares of the company’s stock, valued at approximately $14,874,937.66. This trade represents a 30.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.98% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on IDXX shares. Barclays began coverage on IDEXX Laboratories in a research note on Monday, December 8th. They issued an “overweight” rating and a $850.00 price objective for the company. Wall Street Zen cut shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 17th. UBS Group raised their price target on shares of IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 4th. Morgan Stanley upped their price objective on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a research note on Tuesday, November 4th. Finally, BTIG Research increased their price objective on shares of IDEXX Laboratories from $785.00 to $830.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $763.50.

IDEXX Laboratories Stock Up 0.4%

Shares of NASDAQ IDXX opened at $693.85 on Monday. The company has a market capitalization of $55.40 billion, a P/E ratio of 55.02, a P/E/G ratio of 3.71 and a beta of 1.67. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.18 and a quick ratio of 0.87. The company has a 50 day simple moving average of $705.83 and a 200-day simple moving average of $656.34. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, November 3rd. The company reported $3.22 EPS for the quarter, beating analysts’ consensus estimates of $3.14 by $0.08. The firm had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.The firm’s quarterly revenue was up 13.3% on a year-over-year basis. During the same period in the prior year, the firm posted $2.80 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. On average, equities research analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.